Objectif
The opportunity to focus on the production of biopharmaceuticals is often taken from SMEs since huge amount of resources is required for the development of high-producer cell lines. We envision that our parental cell factories will increase the efficiency of cell line engineering and will effectively reduce the time-to-market for mammalian cell-based products. It allows SMEs to leverage their traditional strengths of adaptability and creativity, and to develop novel products for biotechnology industries.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
61713 Kambja Vald
Estonie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.